TW202203908A - 截短側耳素類之醫療用途 - Google Patents

截短側耳素類之醫療用途 Download PDF

Info

Publication number
TW202203908A
TW202203908A TW110113773A TW110113773A TW202203908A TW 202203908 A TW202203908 A TW 202203908A TW 110113773 A TW110113773 A TW 110113773A TW 110113773 A TW110113773 A TW 110113773A TW 202203908 A TW202203908 A TW 202203908A
Authority
TW
Taiwan
Prior art keywords
hydroxy
mutilin
acetyl
cyclohexylthio
compound
Prior art date
Application number
TW110113773A
Other languages
English (en)
Chinese (zh)
Inventor
麥可 哈夫納
蘇珊娜 波納
沃爾夫岡 維恰
羅森馬里 瑞德
茲林卡 艾維克史恩菲德
Original Assignee
奧地利商納畢瓦治療有限責任公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 奧地利商納畢瓦治療有限責任公司 filed Critical 奧地利商納畢瓦治療有限責任公司
Publication of TW202203908A publication Critical patent/TW202203908A/zh

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C321/00Thiols, sulfides, hydropolysulfides or polysulfides
    • C07C321/12Sulfides, hydropolysulfides, or polysulfides having thio groups bound to acyclic carbon atoms
    • C07C321/16Sulfides, hydropolysulfides, or polysulfides having thio groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
TW110113773A 2020-04-17 2021-04-16 截短側耳素類之醫療用途 TW202203908A (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202063011474P 2020-04-17 2020-04-17
US63/011,474 2020-04-17
EP20170072 2020-04-17
EP20170072.1 2020-04-17
EP20183292 2020-06-30
EP20183292.0 2020-06-30

Publications (1)

Publication Number Publication Date
TW202203908A true TW202203908A (zh) 2022-02-01

Family

ID=75801547

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110113773A TW202203908A (zh) 2020-04-17 2021-04-16 截短側耳素類之醫療用途

Country Status (9)

Country Link
US (1) US20230174472A1 (https=)
EP (1) EP4135682A1 (https=)
JP (2) JP2023522644A (https=)
CN (1) CN115443131A (https=)
BR (1) BR112022020007A2 (https=)
CA (1) CA3180535A1 (https=)
IL (1) IL297268A (https=)
TW (1) TW202203908A (https=)
WO (1) WO2021209174A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4475834A1 (en) 2022-02-09 2024-12-18 Nabriva Therapeutics GMBH Lefamulin and its derivatives for use in the treatment of a spiral shaped bacteria
EP4338732A1 (en) 2022-09-16 2024-03-20 Nabriva Therapeutics GMBH Lefamulin and its derivatives for use in the treatment of tularemia
CN119925362A (zh) * 2023-11-03 2025-05-06 阳光安津(南京)生物医药科技有限公司 一种化合物在制备用于治疗银屑病的药物中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7790767B2 (en) * 2005-06-27 2010-09-07 Nabriva Therapeutics Forschungs Gmbh Pleuromutilin derivatives containing a hydroxyamino- or acyloxyaminocycloalkyl group
EP1972618A1 (en) * 2007-03-20 2008-09-24 Nabriva Therapeutics AG Pleuromutilin derivatives for the treatment of diseases mediated by microbes
GB0803707D0 (en) * 2008-02-28 2008-04-09 Cambridge Entpr Ltd Antiviral agent
EP2399904A1 (en) * 2010-05-26 2011-12-28 Nabriva Therapeutics AG Process for the preparation of pleuromutilins
CN103204787B (zh) 2012-01-17 2014-10-01 北京艾百诺科技有限公司 含有取代方酸的乙酸妙林酯及其应用
CN103242210B (zh) 2012-02-09 2014-09-24 北京艾百诺科技有限公司 含有取代方酸的乙酸妙林酯及其应用
ES2843723T3 (es) 2015-06-17 2021-07-20 Nabriva Therapeutics GmbH Formulaciones farmacéuticas inyectables de lefamulina
CN110507823B (zh) * 2019-08-20 2021-08-24 中国医学科学院基础医学研究所 衣康酸相关物质在诊断、防治病毒感染性疾病中的应用

Also Published As

Publication number Publication date
US20230174472A1 (en) 2023-06-08
CN115443131A (zh) 2022-12-06
JP2023522644A (ja) 2023-05-31
WO2021209174A1 (en) 2021-10-21
JP2026041886A (ja) 2026-03-10
IL297268A (en) 2022-12-01
CA3180535A1 (en) 2021-10-21
EP4135682A1 (en) 2023-02-22
BR112022020007A2 (pt) 2022-11-22

Similar Documents

Publication Publication Date Title
JP2026041886A (ja) プレウロムチリンの治療的使用
EP4135683B1 (en) Antiviral use of pleuromutilins
EP3728289B1 (en) Optimised compounds
KR20150013527A (ko) 항염증 활성과 접합된 증진된 항인플루엔자제
EP3556377A1 (en) Antiviral immunotropic agent for the treatment of acute respiratory viral infections
US20230150984A1 (en) Nicotinamide mononucleotide and nicotinamide riboside derivatives and use thereof in the treatment of viral infections and respiratory complications, in particular caused by influenzavirus or coronavirus
WO2020241759A1 (ja) インフルエンザウイルス感染症またはコロナウイルス感染症の予防および/または治療剤
US11965006B2 (en) Antimicrobial and anti-cancer therapy
WO2004108122A1 (en) Glycyrrhizin or derivatives thereof for treating or preventing severe acute respiratory syndrome (sars)
JP2023520917A (ja) 呼吸器状態を処置するためのtrpc6阻害剤
KR20090102850A (ko) 항바이러스 화합물
EP4135681B1 (en) Antiviral use of pleuromutilins
US20180066018A1 (en) Conformationally stable analogs of the response selective c5a agonist ep67
MX2012005551A (es) Tratamiento de infecciones microbianas.
EP4125924B1 (en) Furosemide compositions for use in supportive therapy in coronavirus infection
EP3720440A1 (en) Treatment of rsv with combination product
JP2009533428A (ja) 筋肉内抗ウイルス処置
JPH05310578A (ja) ミゾリビンを有効成分とする感染疾患の予防または治療剤
WO2025231155A2 (en) Methods for reducing or preventing sars-cov-2 infection and transmission
EP3949964A1 (en) Combination of nicotinamide mononucleotide derivatives and other therapeutic agents for use in the treatment of viral infections
Walker American Thoracic Society (ATS) 2014 International Conference-San Diego, California, USA-May 16-21, 2014